A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes
Phase of Trial: Phase II
Latest Information Update: 16 Sep 2015
At a glance
- Drugs Bempedoic acid (Primary)
- Indications Hyperlipidaemia
- Focus Therapeutic Use
- Sponsors Esperion Therapeutics
- 02 May 2013 Primary endpoint 'Reduction in LDL-cholesterol-level' has been met.
- 02 May 2013 Results presented at the Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB) 2013 Scientific Sessions and reported in a Esperion Therapeutics media release.
- 07 Jan 2013 The full data from this trial will be presented at a future scientific meeting, according to an Esperion Therapeutics media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History